TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a sell rating to a hold rating in a research report released on Sunday morning.

A number of other equities analysts have also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Lake Street Capital dropped their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Stock Down 1.6%

Shares of NASDAQ TLSI opened at $5.03 on Friday. The firm has a market capitalization of $309.75 million, a PE ratio of -3.87 and a beta of 0.43. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. TriSalus Life Sciences has a 1 year low of $2.20 and a 1 year high of $7.95. The firm’s 50-day moving average is $4.61 and its 200-day moving average is $4.32.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $11.41 million for the quarter, compared to analyst estimates of $10.27 million.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of TLSI. Cura Wealth Advisors LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter valued at approximately $36,000. JPMorgan Chase & Co. grew its holdings in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in TriSalus Life Sciences in the second quarter valued at approximately $47,000. Invesco Ltd. bought a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $72,000. Finally, Abel Hall LLC acquired a new stake in TriSalus Life Sciences in the fourth quarter worth $73,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.